Our clinical development plan represents a staged strategy to maximize the benefit for increasingly broader groups of patients.

1. Initiate the Phase 3 sTEADfast study in 2nd and 3rd line Mesothelioma patients previously treated with both immunotherapy and chemotherapy.
2. Prolong progression-free survival by combining VT3989 with standard of care immunotherapy and chemotherapy regimens in first line Mesothelioma patients in Phase 2 expansion cohorts.
3. Demonstrate proof of concept of VT3989 synergy and resistance prevention to other targeted agents such as EGFR inhibitors, KRAS G12C inhibitors and panRAS(on) inhibitors.